Hence, for patients with advanced NSCLC, ESMO recommends determining PD-L1 expression between others such as EGFR testing, BRAF mutations, and the analysis of ALK, ROS1, and NTRK rearrangements [71]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.